Contrasting Tandem Diabetes Care (NASDAQ:TNDM) and Carmell (NASDAQ:CTCX)

Tandem Diabetes Care (NASDAQ:TNDM) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Profitability

This table compares Tandem Diabetes Care and Carmell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-14.84%	-44.19%	-11.99%
Carmell	N/A	-217.50%	-50.22%

Institutional & Insider Ownership

24.2% of Carmell shares are owned by institutional investors. 2.2% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 29.0% of Carmell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Tandem Diabetes Care and Carmell”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$940.20 million	1.18	-$222.61 million	($1.46)	-11.41
Carmell	$32,839.00	79.32	-$15.44 million	N/A	N/A

Carmell has lower revenue, but higher earnings than Tandem Diabetes Care.

Analyst Recommendations

This is a summary of recent ratings for Tandem Diabetes Care and Carmell, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	0	8	11	0	2.58
Carmell	0	0	0	0	0.00

Tandem Diabetes Care presently has a consensus target price of $43.88, suggesting a potential upside of 163.40%. Given Tandem Diabetes Care’s stronger consensus rating and higher probable upside, research analysts plainly believe Tandem Diabetes Care is more favorable than Carmell.

Risk & Volatility

Tandem Diabetes Care has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Tandem Diabetes Care beats Carmell on 7 of the 12 factors compared between the two stocks.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.